不同维生素D制剂对长期从事室内工作的女性血25-羟维生素D水平的影响

摘要

Objective To explore effects of different dosage forms of vitamin D on the serum 25 - hydroxy vitamin D [25 (OH) D]of female healthy adults working indoor in Chengdu. Methods In Sept 2011 , 80 participants enrolled at the Affiliated Hospital of Chengdu University were randomized into vitamin D, injection group [ Group D2, n = 20, vitamin D2 injection 10 mg ( 400 000 U ) every two weeks for one times ], oral Caltrate tablet ( calcium 600 mg and vitamin D3 125 U ) group ( Group D3 125 , n = 20 , one tablet everyday ), Centrum Tablets ( contained vitamin D3 400 U ) group ( Group D3 400, n = 20 , one tablet everyday ) and Caltrate tablet plus Centrum Tablets group ( Group D3 525 U, n =20, one tablet of the two everyday ). The serum 25 ( OH ) D were measured after two months therapy. Results Among completing over 85 % therapy participants included in the results, there were 18 cases of Group D2, 15 cases of Group D3 125 , 13 case of Group D3 400 , 14 cases of Group D3 525. No significant differences were observed in the serum 25 ( OH ) D level of four groups subjects before the therapy ( P > 0. 05 ) . The serum 25 ( OH ) D level of Group D2, Group D3 125 , Group D3 400 and Group D3 525 after therapy were ( 59. 0 ± 24. 9 ), ( 28. 6 ± 13. 6 ), ( 30. 4 ± 16. 6 ) and ( 40. 0 ± 14. 9 ) nmol/L respectively ( P < 0. 01 ) .The serum 25 ( OH ) D level of Group D2 after treatment were significantly higher than before [( 33.05 ±11. 10) nmol/L, P<0.01 ] and other 3 groups ( P <0. 01 ) . Conclusion High - dosage vitamin D2 injection can improve the serum 25 ( OH ) D level of female healthy adults working indoor in Chengdu city, oral vitamin D or vitamin D tablets ( contained VitD3 125 ~525 U ) has no distinct improvement in vitamin D condition.%目的 探讨不同维生素D(VitD)制剂对长期从事室内工作的女性血25-羟维生素D[25(OH)D]水平的影响.方法 2011年9月成都大学附属医院招募了80例长期从事室内工作的体检健康女性,将其随机分为维生素D2注射组(孚泰组)、碳酸钙D3片组(钙尔奇D3组)、多维元素片组(善存组)及联合组,各20例.孚泰组给予孚泰针剂10 mg/次(40万U/次),每半月1次;钙尔奇D3组给予钙尔奇D3(含元素钙600 mg+VitD3 125 U)1片/d口服;善存组给予善存(含VitD3 400 U)1片/d口服;联合组给予钙尔奇D3和善存各1片/d口服,即含VitD3 525 U.均治疗2个月,观察各组治疗前后血25(OH)D水平变化.结果 对于完成治疗85%以上的人群纳入结果分析,其中孚泰组18例,钙尔奇D3组15例,善存组13例,联合组14例.治疗前4组受试者血25(OH)D水平比较,差异无统计学意义(P＞0.05);治疗后孚泰组、钙尔奇D3组、善存组、联合组血25(OH)D水平分别为(59.0±24.9)、(28.6±13.6)、(30.4±16.6)、(40.0±14.9)nmol/L,差异有统计学意义(P＜0.01);其中孚泰组血25(OH)D水平高于治疗前(33.0±11.1)nmol/L,差异有统计学意义(P＜0.01);且治疗后孚泰组血25(OH)D水平高于其他3组,差异均有统计学意义(P＜0.01).结论 肌肉注射大剂量VitD2能明显改善机体VitD营养状况,而口服VitD或含VitD制剂(含VitD3 125~525 U)对机体VitD营养状况无明显改善.